MedTrace Logo

Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

NCT02303002 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2016-03-09

No results posted yet for this study

Summary

This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.

Conditions

  • Glabellar Frown Lines

Interventions

BIOLOGICAL

Botulinum Toxin Type A

Intramuscular injection (IM)

BIOLOGICAL

Active Comparator botulinum toxin

IM injection

BIOLOGICAL

Placebo Comparator

IM injection

Sponsors & Collaborators

  • Revance Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303002 on ClinicalTrials.gov